[1] |
ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali.
Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
|
[2] |
YE Kaili, ZHENG Wen, YE Qifa, YANG Lan .
Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1086-1094.
|
[3] |
YU Saihong, ZHENG Xiaoliang, PU Yiyi, YAN Dongmei, WANG Xiaoju, YU Jie.
Reversal of 5-fluorouracil resistance in hepatocellular carcinoma cells by inhibiting ribonucleotide reductase M2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 729-737.
|
[4] |
SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo.
Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
|
[5] |
HE Jiaqi, LI Juanjuan, LV Xiaoai, ZHANG Huanhuan, YU Chenhuan.
Reversal effects and mechanisms of Flavonoids from Tetrastigma hemsleyanum on drug resistance in gefitinib-resistant lung cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 368-375.
|
[6] |
CHEN Minfang, CHEN Lihua, XIE Liyun, XU Fenfen, XIA Aixiao, LIN Zhong.
Preparation and the effect of antitumor of DNA plasmid lipidosome vaccine based VEGFR2 extracellular region by immunization activated in vitro
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 24-29.
|
[7] |
HUANG Kang, LI Ling, YE Qifa, PENG Guizhu.
Expression of long non-coding RNA LINC00844 in hepatocellular carcinoma and its inhibiting effect on cell proliferation and migration
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 366-372.
|
[8] |
CHANG Qingqing, PENG Ying, WANG Guangji, SUN Jianguo.
Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 948-956.
|
[9] |
YANG Shucai,ZHANG Li,LIU Liping,DENG Weijie,ZHOU Jie,LIU Hui,ZHANG Baohu,JIN Tao.
Effect of hypoxia-inducible factor 2α on chemoresistance of hepatocellular carcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 630-636.
|
[10] |
BAI Xuemin, ZOU Likao, JIN Zhenmu, JIANG Lijia.
Effects of N-acetylcysteine on regulation of EGFR/MAPK signaling pathway in airway mucus hypersecretion in chronic obstructive pulmonary disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1120-1127.
|
[11] |
TIAN Jing, MENG Qiuhua, LIANG Qiuyun, DONG Min.
Research progress in the associations of metabolic diseases and therapeutic drugs with hepatocellular carcinomas
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 103-110.
|
[12] |
YUAN Gang, HU Airong, HU Yaoren, ZENG Chuanli, ZHU Dedong, SHI Xiaojun.
Clinical efficacy and long-term prognosis of entecavir and adefovir dipivoxil in the treatment of compensatory hepatitis B cirrhosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 170-174.
|
[13] |
CAI Min, XU Liu, SHEN Lan, ZHANG Jie.
Expression of long-chain non-coding RNA FOXN3-AS2 in hepatocellular carcinoma and its effect on proliferation and invasion of hepatoma cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1246-1251.
|
[14] |
WANG Lu, ZHENG Xin, WANG Weicong, ZHAO Hongyun, MA Yuxiang, ZHANG Li, HU Pei, JIANG Ji.
Pharmacokinetics of the metabolites of abivertinib in Chinese patients with advanced NSCLC in a single and multiple dose group
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1147-1152.
|
[15] |
YUAN Shaofei, ZHU Linjia, ZHENG Weie, LIANG Meizhen.
Relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 927-932.
|